Association of HTR1A Gene Polymorphisms with Efficacy and Plasma Concentrations of Atypical Antipsychotics in the Treatment of Male Patients with Schizophrenia

References

• Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–1222. doi:10.1016/S0140-6736(20)
   PubMed Web of Science ®Google Scholar
• Weyant C, Brandeau ML, Basu S. Personalizing Medical Treatment Decisions: integrating Meta-analytic Treatment Comparisons with Patient-Specific Risks and Preferences. Med Decis Mak. 2019;39(8):998–1009. doi:10.1177/0272989X19884927
   PubMed Web of Science ®Google Scholar
• Dev R, Li J, Zhang D, et al. An economic evaluation of a mobile text messaging intervention to improve mental health care in resource-poor communities in China: a cost-effectiveness study. BMC Health Serv Res. 2020;20(1):989. doi:10.1186/s12913-020-05855-6
   PubMed Web of Science ®Google Scholar
• Nayak R, Rosh I, Kustanovich I, Stern S. Mood Stabilizers in Psychiatric Disorders and Mechanisms Learnt from In Vitro Model Systems. Int J Mol Sci. 2021;22(17):9315. doi:10.3390/ijms22179315
   PubMed Web of Science ®Google Scholar
• Guan F, Lin H, Chen G, et al. Evaluation of association of common variants in HTR1A and HTR5A with schizophrenia and executive function. Sci Rep. 2016;6(1):38048. doi:10.1038/srep38048
   PubMedGoogle Scholar
• Ng IS, Chua J, Lui Y, Tan L, Teo DS. Approach to acute psychosis in older adults. Singapore Med J. 2023;64(6):391. doi:10.4103/singaporemedj.SMJ-2022-150
   PubMed Web of Science ®Google Scholar
• Lodge D, Perez S. New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways. Drug Des Devel Ther. 2014;887. doi:10.2147/DDDT.S42708
   PubMed Web of Science ®Google Scholar
• Chilmonczyk Z, Bojarski A, Pilc A, Sylte I. Functional Selectivity and Antidepressant Activity of Serotonin 1A Receptor Ligands. Int J Mol Sci. 2015;16(8):18474–18506. doi:10.3390/ijms160818474
   PubMed Web of Science ®Google Scholar
• Haleem DJ. 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson’s disease and schizophrenia. Behav. Pharmacol. 2015;26:45–58. doi:10.1097/FBP.0000000000000123
   PubMed Web of Science ®Google Scholar
• Mlambo R, Liu J, Wang Q, Tan S, Chen C. Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders. Pharmaceuticals. 2023;16(4):603. doi:10.3390/ph16040603
   Web of Science ®Google Scholar
• Riga MS, Lladó-Pelfort L, Artigas F, Celada P. The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice: regionally-selective involvement of 5-HT1A and 5-HT2A receptors. Neuropharmacology. 2018;142:219–230. doi:10.1016/j.neuropharm.2017.11.049
   PubMed Web of Science ®Google Scholar
• Filip M, Bader M. Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system. Pharmacol Rep. 2009;61(5):761–777. doi:10.1016/S1734-1140(09)70132-X
   PubMed Web of Science ®Google Scholar
• Asad S, Nikamo P, Gyllenberg A, et al. HTR1A a Novel Type 1 Diabetes Susceptibility Gene on Chromosome 5p13-q13. PLoS One. 2012;7(5):e35439. doi:10.1371/journal.pone.0035439
   PubMed Web of Science ®Google Scholar
• Takekita Y, Fabbri C, Kato M, et al. HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia. J Clin Psychopharmacol. 2015;35(3):220–227. doi:10.1097/JCP.0000000000000304
   PubMed Web of Science ®Google Scholar
• Bosia M, Lorenzi C, Pirovano A, et al. COMT Val158Met and 5-HT1A-R −1019 C/G polymorphisms: effects on the negative symptom response to clozapine. Pharmacogenomics. 2015;16(1):35–44. doi:10.2217/pgs.14.150
   PubMed Web of Science ®Google Scholar
• Takekita Y, Fabbri C, Kato M, et al. HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: a Meta-Analysis. Int J Neuropsychopharmacol. 2016;19(5):pyv125. doi:10.1093/ijnp/pyv125
   PubMed Web of Science ®Google Scholar
• Yoshikawa A, Li J, Meltzer HY. A functional HTR1A polymorphism, rs6295, predicts short-term response to lurasidone: confirmation with meta-analysis of other antipsychotic drugs. Pharmacogenomics J. 2020;20(2):260–270. doi:10.1038/s41397-019-0101-5
   PubMed Web of Science ®Google Scholar
• Mössner R, Schuhmacher A, Kühn KU, et al. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet Genomics. 2009;19(1):91–94. doi:10.1097/FPC.0b013e328311a917
   PubMed Web of Science ®Google Scholar
• De Deurwaerdère P, Di Giovanni G. Serotonin in Health and Disease. Int J Mol Sci. 2020;21(10):3500. doi:10.3390/ijms21103500
   PubMed Web of Science ®Google Scholar
• Zhong X, Tong X, Ju Y, Du X, Li Y. Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision? Curr Drug Metab. 2018;19(14):1152–1158. doi:10.2174/1389200219666171227200547
   PubMed Web of Science ®Google Scholar
• Amalinei C. Current Knowledge and Novel Therapeutic Approaches Based on Pharmacokinetics and Pharmacodynamics in Stress-Induced Pathology. Medicina. 2022;58(7):839. doi:10.3390/medicina58070839
   PubMedGoogle Scholar
• Franczyk B, Rysz J, Gluba-Brzózka A. Pharmacogenetics of Drugs Used in the Treatment of Cancers. Genes. 2022;13(2):311. doi:10.3390/genes13020311
   PubMed Web of Science ®Google Scholar
• Johnson BO, Orji G, Johnson OO, et al. Rebound Catatonia Associated With Injectable Paliperidone. Cureus. 2023. doi:10.7759/cureus.40478
   Web of Science ®Google Scholar
• Efron D, Dale RC. Tics and Tourette syndrome. J Paediatr Child Health. 2018;54(10):1148–1153. doi:10.1111/jpc.14165
   PubMed Web of Science ®Google Scholar
• Sugawara Kikuchi Y, Shimizu T. Aripiprazole for the treatment of psychotic symptoms in patients with dementia with Lewy bodies: a case series. Neuropsychiatr Dis Treat. 2019;15:543–547. doi:10.2147/NDT.S189050
   PubMed Web of Science ®Google Scholar
• Xu X, Li S, Luan X, et al. Sensitivity enhancement of a Cu (II) metal organic framework-acetylene black-based electrochemical sensor for ultrasensitive detection of imatinib in clinical samples. Front Chem. 2023:11. doi:10.3389/fchem.2023.1191075
   Web of Science ®Google Scholar
• Zhang L, Brown SJ, Shan Y, et al. CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: a Systematic Review and Meta‐analysis. Pharmacotherapy. 2020;40(7):632–647. doi:10.1002/phar.2434
   PubMed Web of Science ®Google Scholar
• Jukic MM, Smith RL, Haslemo T, Molden E, Ingelman-Sundberg M. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. Lancet Psychiatry. 2019;6(5):418–426. doi:10.1016/S2215-0366(19)30088-4
   PubMed Web of Science ®Google Scholar